CIM
EWTX icon

Contravisory Investment Management’s Edgewise Therapeutics EWTX Stock Holding History

Contravisory Investment Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,209
Closed -$225K – 399
2025
Q1 		$225K Buy
+10,209
New +$268K 0.05% 233

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Contravisory Investment Management's EWTX Position: Q2 2025 in Review

Contravisory Investment Management sold out of Edgewise Therapeutics (EWTX) in Q2 2025, closing a stake of 10,209 shares — an estimated $225K sold.

Contravisory Investment Management first reported a position in EWTX in Q1 2025 and held it in 1 quarter. The position peaked at $225K in Q1 2025. 178 funds tracked by Wall St. Rank hold EWTX as of Q2 2025.

  • Contravisory Investment Management reported no remaining Edgewise Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Contravisory Investment Management sold 10,209 Edgewise Therapeutics shares in Q2 2025, an estimated $225K.
  • Contravisory Investment Management first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 1 quarter.
  • Contravisory Investment Management's Edgewise Therapeutics position peaked at $225K in Q1 2025.
  • 178 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2025.

Based on Contravisory Investment Management's 13F filing for Q2 2025, filed 10 Jul 2025.